Literature DB >> 3871161

Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma.

G Juliusson, K H Robèrt, A Ost, K Friberg, P Biberfeld, B Nilsson, L Zech, G Gahrton.   

Abstract

Fifty-five patients with a clonal expansion of B lymphocytes in the peripheral blood were studied. According to the Kiel classification, 22 patients had chronic lymphocytic leukemia (CLL), 29 had immunocytoma (IC), two had prolymphocytic leukemia, and one had centrocytic lymphoma; one was not subclassified. Cytogenetic studies after B cell mitogen stimulation showed that six patients had an extra chromosome 12 as the sole abnormality. Another ten patients had an extra chromosome 12 together with other abnormalities. One patient had dup(12). Fifteen patients showed clonal aberrations without +12. Eleven patients showed only normal metaphases, and 12 patients were not evaluated cytogenetically. The cytogenetic subgroup pattern did not distinguish between CLL and IC patients. There was no significant difference between the CLL and IC groups as regards clinical findings and prognosis. However, the cytogenetic typing proved to be of prognostic significance. Increasing numbers of chromosomal aberrations within the cell clone were significantly associated with a poorer prognosis, ie, with impairment of survival (P = .04) and therapy-free survival (P less than 10(-4]. Patients with complex karyotypes (at least clonal aberrations) showed the poorest survival (P = .007). Patients with +12 required treatment earlier than patients with a normal karyotype (P = .01) and patients with karyotypic changes other than +12 (P = .006). These latter differences were even more pronounced when only IC patients were considered (P = .005 and P = .002, respectively). A multivariate analysis revealed that +12 was as strong an indicator of poor survival as advanced Rai or Binet stages and a stronger predictor of therapy-demanding disease.

Entities:  

Mesh:

Year:  1985        PMID: 3871161

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.

Authors:  J A Woyach; G Lozanski; A S Ruppert; A Lozanski; K A Blum; J A Jones; J M Flynn; A J Johnson; M R Grever; N A Heerema; J C Byrd
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

2.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

3.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

4.  Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Authors:  Rebeqa Gunnarsson; Larry Mansouri; Anders Isaksson; Hanna Göransson; Nicola Cahill; Mattias Jansson; Markus Rasmussen; Jeanette Lundin; Stefan Norin; Anne Mette Buhl; Karin Ekström Smedby; Henrik Hjalgrim; Karin Karlsson; Jesper Jurlander; Christian Geisler; Gunnar Juliusson; Richard Rosenquist
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

5.  Chromosomes, genes, and cancer.

Authors:  P C Nowell; C M Croce
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

6.  Chronic lymphocytic leukaemia presenting with central nervous system involvement.

Authors:  L Poplawska-Szczyglowska; J Walewski; B Pienkowska-Grela; G Rymkiewicz; O Mioduszewska
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

7.  Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

Authors:  Nyla A Heerema; John C Byrd; Paola S Dal Cin; Marie L Dell' Aquila; Prasad R K Koduru; Ayala Aviram; Stephanie A Smoley; Laura Z Rassenti; Andrew W Greaves; Jennifer R Brown; Kanti R Rai; Thomas J Kipps; Neil E Kay; Daniel L Van Dyke
Journal:  Cancer Genet Cytogenet       Date:  2010-12

8.  Establishment and characterization of a new Epstein-Barr virus transformed cell line from a human B cell lymphoma.

Authors:  O Janssen; B Heinze; C R Bartram; M Pawlita; T Binder; H Heimpel; K Diehl; D Kabelitz
Journal:  Blut       Date:  1990-03

9.  Nuclear DNA content of non-endemic Burkitt's lymphoma.

Authors:  T Lehtinen; M Lehtinen; R Aine; O P Kallioniemi; T Leino; T Hakala; P Leinikki; M Alavaikko
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

10.  Cytogenetic markers in hematoproliferative disorders.

Authors:  C Fonatsch
Journal:  Blut       Date:  1985-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.